دورية أكاديمية
[Checkpoint inhibitor induced diabetes mellitus].
| العنوان: | [Checkpoint inhibitor induced diabetes mellitus]. |
|---|---|
| عنوان ترانسليتريتد: | Checkpointremmer geïnduceerde diabetes mellitus. |
| المؤلفون: | Leentjens J; Radboudumc, afd. Interne Geneeskunde, Nijmegen.; Contact: J. Leentjens (jenneke.leentjens@radboudumc.nl)., Olde Bekkink M; Radboudumc, afd. Interne Geneeskunde, Nijmegen., Koot R; Radboudumc, afd. Interne Geneeskunde, Nijmegen., Herbschleb KH; Radboudumc, afd. Interne Geneeskunde, Nijmegen., de Galan BE; Radboudumc, afd. Interne Geneeskunde, Nijmegen. |
| المصدر: | Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2019 Aug 19; Vol. 163. Date of Electronic Publication: 2019 Aug 19. |
| نوع المنشور: | Journal Article |
| اللغة: | Dutch; Flemish |
| بيانات الدورية: | Publisher: Vereniging NTvG Country of Publication: Netherlands NLM ID: 0400770 Publication Model: Electronic Cited Medium: Internet ISSN: 1876-8784 (Electronic) Linking ISSN: 00282162 NLM ISO Abbreviation: Ned Tijdschr Geneeskd Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017?-: Amsterdam : Vereniging NTvG Original Publication: Houten : Bohn Stafleu van Loghum |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized/*administration & dosage , Antineoplastic Agents, Immunological/*immunology , Diabetes Mellitus, Type 1/*drug therapy , Diabetes Mellitus, Type 1/*immunology, Cell Cycle Checkpoints/immunology ; Female ; Humans ; Insulin ; Male |
| مستخلص: | BACKGROUND Checkpoint inhibitors are relatively new anti-cancer medicines that activate tumour cell immunity. CASE DESCRIPTION We describe two patients who presented to the emergency department due to severe ketoacidosis, this being the first symptom of diabetes in said patients. A few weeks prior to this, they each commenced treatment with the checkpoint inhibitor pembrolizumab. HbA1c level, assessed in one of the patients, was not elevated upon presentation. CONCLUSION Type 1 diabetes mellitus is a rare, but potentially life-threatening, complication of treatment with checkpoint inhibitors. However, routine measurement of glucose or HbA1c levels is not useful in patients who are treated with checkpoint inhibitors. Both patients and healthcare professionals should be (made) aware of the symptoms of hyperglycaemia, thereby ensuring immediate treatment with insulin in order to prevent severe ketoacidosis. |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 0 (Antineoplastic Agents, Immunological) 0 (Insulin) DPT0O3T46P (pembrolizumab) |
| تواريخ الأحداث: | Date Created: 20190822 Date Completed: 20191223 Latest Revision: 20200109 |
| رمز التحديث: | 20231215 |
| PMID: | 31433147 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1876-8784 |
|---|